Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Medicenna Therapeutics Corp (MDNAF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.4000 +0.0100    +0.72%
15:55:00 - Closed. Currency in USD ( Disclaimer )
After Hours
1.4321
+0.0321
+2.2929%
15:55:36 - Delayed Data
Type:  Equity
Market:  United States
  • Volume: 118,392
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.3360 - 1.4700
Medicenna 1.4000 +0.0100 +0.72%

Medicenna Therapeutics Corp Company Profile

 
Get an in-depth profile of Medicenna Therapeutics Corp, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

18

Equity Type

ORD

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Contact Information

Address 2 Bloor Street West 7th Floor
Toronto, M4W 3E2
Canada
Phone 416- 648-5555
Fax -

Top Executives

Name Age Since Title
Fahar Merchant 66 2011 Founder, Chairman, President & CEO
John H. Sampson 56 2021 Independent Director
Albert George Beraldo 70 2016 Lead Independent Director
Karen A. Dawes 71 2019 Independent Director
Sergio A. Quezada 47 2022 Chairman of Scientific Advisory Board
John Geltosky 77 2020 Independent Director
William L. Redmond - 2022 Member of Scientific Advisory Board
Kapil Dhingra 64 2022 Strategic Advisor
David J. Mooney - 2022 Member of Scientific Advisory Board
Paolo Antonio Ascierto - 2022 Member of Clinical Advisory Board
Lillian L. Siu - 2022 Member of Clinical Advisory Board
Burkhard Becher - 2022 Member of Scientific Advisory Board
Hussein A. Tawbi - 2022 Member of Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MDNA Comments

Write your thoughts about Medicenna Therapeutics Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
QTRADING SOLUTION
3QTS Jan 12, 2023 3:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
EPS: Total Earnings (see P&L statement bottom line) / Number of shares outstanding (see BS equity capital line)
ADEDIRAN IBRAHIM SUARA
ADEDIRAN IBRAHIM SUARA Jun 28, 2021 4:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
pls,what is eps?
Peter Ballsnbush
BoyYeetzWorld Dec 28, 2020 4:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀 off we go
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email